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Abstract Retinoblastoma (RB) is the most common primary intraocular malignancy in children. Somatic inac-
 tivation of both alleles of the RB1 tumor suppressor gene in a developing retina is a crucial event 
in the initiation of tumorigenesis in most cases of isolated unilateral retinoblastoma. We analyzed the DNA from 
tumor tissue and peripheral blood of a unilateral retinoblastoma patient to determine the RB1 mutation status 
and to provide an accurate genetic counseling. A comprehensive approach, based on our previous experience, 
was used to identify the causative RB1 mutations. Screening for RB1 mutations was performed by PCR direct 
sequencing, multiplex ligation-dependent probe amplification (MLPA) and Real Time-PCR analyses. Three dif-
ferent mutations were identified in the tumor DNA, which were absent in blood DNA. The somatic origin of these 
mutations was vital to rule out the heritable condition in this patient.
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Resumen Mutaciones somáticas raras en un paciente con retinoblastoma unilateral.  El retinoblastoma
 (RB) es el cáncer ocular más común de la niñez. La inactivación somática de ambos alelos del gen 
supresor de tumores RB1 en la retina en desarrollo es un evento crucial en la iniciación de la tumorigénesis en 
la mayoría de los casos de retinoblastoma unilateral. Nosotros analizamos el ADN de tumor y de sangre perifé-
rica de un paciente con retinoblastoma unilateral para identificar las mutaciones y así proveer un asesoramiento 
genético a la familia. Para ello utilizamos un protocolo basado en nuestra previa experiencia para identificar 
todas las mutaciones en el gen RB1 que causaron el RB. El rastreo de mutaciones se realizó por medio de los 
siguientes análisis: PCR-secuenciación, amplificación multiplex de sondas ligadas (MLPA) y PCR-Tiempo Real. 
Se encontraron tres mutaciones diferentes en el ADN del tumor, las cuales estaban ausentes en el ADN de la 
sangre. El origen somático de estas mutaciones es importante para indicar que la enfermedad no es hereditaria.
Palabras clave: retinoblastoma, gen supresor tumoral RB1, mutaciones
Recibido: 5-III-2015 Aceptado: 4-V-2015
Postal address: Dra. Irene Szijan, Facultad de Farmacia y Bioquímica, 
Universidad de Buenos Aires, Junín 956, 1113 Buenos Aires, Argentina
e-mail: iszijan@ffyb.uba.ar
Though the incidence of retinoblastoma (RB) is low 
(15.3-42.5 per million children aged 0-4) it appears as a 
hereditary cancer in approximately 50% of cases, thus, it 
is crucial to be diagnosed for its hereditary predisposition1. 
RB may be either bilateral (approximately 40%) or unilat-
eral (60%), the former is caused by a germ-line mutation 
in one RB1 allele, which may be inherited (10%) or arisen 
“de novo”, followed by a somatic mutation in the other al-
lele. Unilateral RB is caused in most cases (approximately 
80%) by two somatic mutations2. Mutations in both RB1 
alleles result in a loss of function of a retinoblastoma pro-
tein, leading to deregulation of cell proliferation and tumor 
development. RB may be diagnosed by several presenting 
signs such as leukocoria or strabismus. An early diagnosis 
is critical for survival and eye preservation in children who 
carry the mutation. The most common treatment for RB 
in developing countries is enucleation, with or without 
adjuvant chemotherapy according to tumor presentation3.
Screening for RB1 mutations is challenging because 
of their heterogeneity and their distribution along the 
RB1 exons, the promoter region and the flanking intronic 
sequences4. Moreover, only few mutations on specific 
sites are recurrent, such as the C > T transitions at the 
CpG dinucleotides. Most of mutations are unique or 
rarely reported (Retinoblastoma Mutation Data Base)5. 
Approaches using several techniques for mutation analy-
sis may detect alterations in the RB1 gene in about 80 to 
90% of patients with germ-line mutations6-8. However, half 
of the RB patients do not carry mutations in constitutional 
DNA but they do only in tumor tissue, which is not readily 
available.   
Most of the RB1 mutations are nonsense or frame-shift 
including nonsense substitutions, large deletions, small 
deletions or insertions and splice site mutations. All these 
mutations result in an absence of retinoblastoma protein. 
Some RB1 mutations such as missense, in frame dele-
tions or promoter mutations are less common. This type 
of mutations is associated with low penetrance, consist-
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ing in fewer tumors (unilateral RB). In this regard, it is 
noteworthy that some unilateral RB patients carry a low 
penetrant germ-line mutation7, 9.   
The unilateral retinoblastoma patient was diagnosed 
at 16 months and treated by enucleation and adjuvant 
chemotherapy. After signing the informed consent, blood 
and tumor biopsy samples were processed for deoxyribo-
nucleic acid (DNA) extraction using the cetyltrimethylam-
monium bromide (CTAB) method (blood) or the proteinase 
K, phenol/chloroform purification and ethanol precipitation 
method (tumor). 
Screening for RB1 mutations was performed as fol-
lows:
1) PCR-direct sequencing of the 27 exons and the 
promoter region of RB1 gene using an ABI 3130XL ge-
netic analyzer9. 
2) Multiplex Ligation-dependent Probe Amplification 
assay (MLPA) using the Salsa MLPA kit PO47-B1 RB1 
(MRC Holland).  
3) Cloning of PCR products in pGEM-T vector: the 
PCR products were ligated to the vector pGEM-T and the 
mixture was transformed into DH5α competent bacteria 
growing in a media with an inducer of ß galactosidase 
(IPTG) and a chromogenic substrate 5-bromo-4chloro-
3-indolyl-ß-galactoside (X-Gal). Recombinant vectors 
produced white colonies, while vectors without an insert 
originated blue colonies. The recombinant vector was ex-
tracted from white colonies and analyzed by sequencing. 
4) Real-Time PCR: quantitative values were obtained 
from a threshold cycle number (Ct) at which an increase 
in the signal, associated with the exponential growth of 
PCR product, begins to be detected. The ΔCt value was 
Fig. 1.– Results of sequence analysis of blood and tumor DNA. A. 56bp duplication in tandem 
in the Exon 11 in tumor DNA and a wild type sequence in the Exon 11 in blood DNA.  
B. G to A transition at the splice donor site of Intron12 in tumor DNA and a wild type sequence 
at the same site in blood DNA. C. Cloning of the PCR product of the tumor Exon 11 reveals 
two different clones, one with a wild type sequence and the other with a mutant sequence, 
confirming thus, the heterozygous duplication g.65432-65487dup in the tumor DNA.
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calculated by normalizing the RB1 exons to the Albumin 
gene, a single copy reference gene. For determination 
of the RB1 gene copy number two exons were selected: 
the mutant exon 11 and the wild type exon 24, using the 
mutated sequence 
5´-TAATTCCTCCACACAGAGA-3´ as a forward primer 
for exon 11 and the primer sequences described in Ot-
taviani et al. (2013)9 as a reverse primer for exon 11 and 
the forward and reverse primers for exon 24. The primer 
sequences for Albumin gene were as follows: 
Fw 5’-TGAAACATACGTTCCCAAAGAGTTT-3’ and 
Rev 5’-CTCTCCTTCTCAGAAAGTGTGCATAT-3’. 
Tumor and constitutional DNA of the patient were assayed 
using as a normal reference the DNA from a pool of 6 
normal individuals. The quantitative PCR was performed in 
a total volume of 25 μl containing 12.5 μl of SYBR Premix 
(Bio-Rad), 2μl of genomic DNA from each of the four se-
rial dilutions containing 60 ng, 30 ng, 15 ng and 7.5 ng of 
DNA, and 5 μl of primers (5 μM each), with two replicates 
per sample. The serial dilutions were performed to test if 
the efficiency of all reactions were comparable in order to 
use the quantitative method.
Fig. 2.– Multiplex ligation-dependent probe amplification (MLPA) analysis of tumor and 
blood DNA. Ratio: sample to reference ratio data. The data above the line of ratio 
1.3 are considered as a duplication of the sequences of centromeric gene (ITM2B), 
the RB1 Exons1 to 27 and the proximal and distal telomeric genes (RCBTB2 and 
DLEU).  621t: Patient´s tumor DNA; 621sp: Patient´s blood DNA; Reference samples 
are the probes for DNA sequences from different human chromosomes. Two of these 
sequences show duplication in patient´s tumor.   
Figures can be seen in color on www.medicinabuenosaires.com
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Mutations were described according to the 
nomenclature10,using the RB1 sequence from the Gen-
Bank, accession No L11910.
Analysis of tumor DNA showed three different muta-
tions in the RB1 gene: 1) in tandem duplication of a 56bp 
sequence in exon 11, g.65432-65487dup (Fig. 1A); 2) a 
base pair substitution at the conserved splice donor site 
of intron 12, c.1215+1G > A (Fig. 1B); 3) a duplication of 
the whole RB1 gene plus the flanking centromeric and 
telomeric genes, g.ITM2B-?_RB1_DLEU+?dup (Fig. 2). 
All these mutations were heterozygous and were absent in 
constitutional DNA. The duplication of 56 bp sequence in 
exon 11 was validated by cloning of exon 11 PCR product 
in pGEM-T vector. Four white colonies were obtained, two 
of them contained the wild type exon 11 and the other 
two the mutant exon 11 (Fig. 1C). These data confirm 
the presence of a heterozygous 56bp duplication in exon 
11. Duplication of the whole RB1 gene was validated by 
Real-Time PCR analysis. The copy number of exons 11 
(mutant) and 24 (wild type) compared with the reference 
gene were determined as follows:
I. ΔΔCt of RB1e24B = (CtRB1e24B-CtAlbuminB)-
(CtRB1e24N-CtAlbuminN)
Where B indicates blood sample of the patient and N 
denotes a pool of normal blood samples. Using the ratio 
equation 2ΔΔCt the relative copy numbers were calculated. 
The expected values were about 1 for a normal dose of 
DNA and 1.5 for heterozygous duplication.
2 ΔΔCt = [ΔCT E-24B (1.21) – ΔCT E-24N (1.18) = ΔΔCt 
0.03] = 1.02
The number of RB1 E-24 copies in blood DNA is similar 
to that of normal individuals
II. ΔΔCt of RB1e24T= (CtRB1e24T-CtAlbuminT)-
(CtRB1e24N-CtAlbuminN)
Where T indicates tumor sample:
2 ΔΔCt = [ΔCT E-24T (1.63) – ΔCT E-24N (1.18) = ΔΔCt 
0.45] = 1.37
The number of RB1 E-24 copies in tumor is 1.37 times 
that of blood
There are 3 copies of RB1 E-24 in tumor and 2 copies 
in blood 
III. ΔΔCt of RB1e11mT= (CtRB1e24T-CtAlbuminT)-
(CtRB1e24T-CtRB1e11mT)
Where E-11mT indicates a mutant Exon 11 in tumor 
DNA:
 2 ΔΔCt = [ΔCT E-24T (1.63) - ΔCT E-11mT (1.08) = ΔΔCt 
0.55] = 1.46
The number of mutant RB1 E-11 copies in DNA is 1/3 
lower than that of RB1 E-24. There were two copies of 
mutant RB1 E-11 and three copies of RB1 E-24 in tumor 
DNA. This analysis revealed that there were three copies 
of RB1 gene in the tumor, two with a duplication of 56bp 
in exon 11 and one copy with a wild type exon 11, but 
presumably carrying the splice site mutation in intron 12.
Molecular genetic testing of RB patients identifies chil-
dren with a heritable condition (approximately 50%), who 
have a genetic predisposition for second tumors11. More-
over, children with unilateral hereditary RB are at risk of 
bilateralization (metachronous bilateral RB)12. Inactivation 
of both alleles of the RB1 tumor suppressor gene requires 
two mutations, being the first of them nonsense or frame 
shifting mutation and the second a chromosomal mutation 
in most of the cases. The results presented here revealed 
three different mutations: 1) frame-shifting insertion in 
exon 11 (novel mutation); 2) donor splice-site mutation in 
intron 12, which is the most common splice-site mutation 
in RB patients, leading to exon 12  skipping and genera-
tion of a stop codon and 3) duplication of a whole RB1 
gene (rarely reported). The presence of three RB1 gene 
mutations in the tumor of the unilateral patient allows us 
to hypothesize that the RB1 gene was inactivated by two 
mutations, an insertion of 56bp in exon 11 of one copy 
and a splice site mutation in intron 12 of the other copy, 
which led to development of the tumor. Later, during the 
continuous proliferation of retinoblasts, probably occurs 
another genetic alteration: duplication of the RB1 copy with 
the mutant exon 11, since there were two copies of the 
mutant exon 11 and three copies of an RB1 exon without 
mutation (exon 24).
This study allowed us to identify two uncommon and 
one recurrent RB1 mutations in the same patient, being 
rare the occurrence of more than two mutations in the 
same tumor. The overall mutation rate of RB is very low, 
RB1 is the only known cancer gene mutated in retino-
blastoma14..More than two RB1 mutations have been 
reported in several RB patients, however most of them 
had undergone neoadjuvant chemotherapy, thus, the 
additional mutations may indicate a chemical damage 
of DNA15. The patient of our study had no chemothera-
peutic treatment before enucleation (when tumor sample 
was isolated) thus, the finding of more than two RB1 
mutations in the same patient is a rare event and may be 
relevant to RB biology. The identification of only somatic 
mutations, which were absent in constitutional tissue of 
a unilateral patient, was useful to rule out the hereditary 
RB predisposition. The data obtained are essential for 
genetic counseling and support the relevance of perform-
ing complete genetic screening for RB1 mutations in both 
tumor and constitutional tissues.
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